Adenosine A2A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder by Freitag, Christine M. et al.
www.ssoar.info
Adenosine A2A receptor gene (ADORA2A) variants
may increase autistic symptoms and anxiety in
autism spectrum disorder
Freitag, Christine M.; Agelopoulos, Konstantin; Huy, Ellen; Rothermundt,
Matthias; Krakowitzky, Petra; Meyer, Jobst; Deckert, Jürgen; Gontard,
Alexander; Hohoff, Christa
Postprint / Postprint
Zeitschriftenartikel / journal article
Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:
www.peerproject.eu
Empfohlene Zitierung / Suggested Citation:
Freitag, C. M., Agelopoulos, K., Huy, E., Rothermundt, M., Krakowitzky, P., Meyer, J., ... Hohoff, C. (2009). Adenosine
A2A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder.
European Child & Adolescent Psychiatry, 19(1), 67-74. https://doi.org/10.1007/s00787-009-0043-6
Nutzungsbedingungen:
Dieser Text wird unter dem "PEER Licence Agreement zur
Verfügung" gestellt. Nähere Auskünfte zum PEER-Projekt finden
Sie hier: http://www.peerproject.eu Gewährt wird ein nicht
exklusives, nicht übertragbares, persönliches und beschränktes
Recht auf Nutzung dieses Dokuments. Dieses Dokument
ist ausschließlich für den persönlichen, nicht-kommerziellen
Gebrauch bestimmt. Auf sämtlichen Kopien dieses Dokuments
müssen alle Urheberrechtshinweise und sonstigen Hinweise
auf gesetzlichen Schutz beibehalten werden. Sie dürfen dieses
Dokument nicht in irgendeiner Weise abändern, noch dürfen
Sie dieses Dokument für öffentliche oder kommerzielle Zwecke
vervielfältigen, öffentlich ausstellen, aufführen, vertreiben oder
anderweitig nutzen.
Mit der Verwendung dieses Dokuments erkennen Sie die
Nutzungsbedingungen an.
Terms of use:
This document is made available under the "PEER Licence
Agreement ". For more Information regarding the PEER-project
see: http://www.peerproject.eu This document is solely intended
for your personal, non-commercial use.All of the copies of
this documents must retain all copyright information and other
information regarding legal protection. You are not allowed to alter
this document in any way, to copy it for public or commercial
purposes, to exhibit the document in public, to perform, distribute
or otherwise use the document in public.
By using this particular document, you accept the above-stated
conditions of use.
Diese Version ist zitierbar unter / This version is citable under:
https://nbn-resolving.org/urn:nbn:de:0168-ssoar-202900
ORIGINAL CONTRIBUTION
Adenosine A2A receptor gene (ADORA2A) variants may increase
autistic symptoms and anxiety in autism spectrum disorder
Christine M. Freitag Æ Konstantin Agelopoulos Æ Ellen Huy Æ
Matthias Rothermundt Æ Petra Krakowitzky Æ Jobst Meyer Æ
Ju¨rgen Deckert Æ Alexander von Gontard Æ Christa Hohoff
Received: 14 November 2008 / Accepted: 10 June 2009 / Published online: 30 June 2009
 Springer-Verlag 2009
Abstract Autism spectrum disorders (ASDs) are hetero-
geneous disorders presenting with increased rates of anxi-
ety. The adenosine A2A receptor gene (ADORA2A) is
associated with panic disorder and is located on chromo-
some 22q11.23. Its gene product, the adenosine A2A
receptor, is strongly expressed in the caudate nucleus,
which also is involved in ASD. As autistic symptoms are
increased in individuals with 22q11.2 deletion syndrome,
and large 22q11.2 deletions and duplications have been
observed in ASD individuals, in this study, 98 individuals
with ASD and 234 control individuals were genotyped for
eight single-nucleotide polymorphisms in ADORA2A.
Nominal association with the disorder was observed for
rs2236624-CC, and phenotypic variability in ASD symp-
toms was influenced by rs3761422, rs5751876 and
rs35320474. In addition, association of ADORA2A variants
with anxiety was replicated for individuals with ASD.
Findings point toward a possible mediating role of
ADORA2A variants on phenotypic expression in ASD that
need to be replicated in a larger sample.
Keywords Autism spectrum disorder  ADORA2A 
Anxiety  Basal ganglia  Caudate nucleus  Glutamate
Introduction
Autism spectrum disorders (ASD) are genetically as well as
phenotypically heterogeneous disorders, which are defined
by qualitative impairments in social interaction and com-
munication as well as stereotyped patterns of behavior and
interests [2]. In addition to autism-specific impairments,
high rates of anxiety disorders are observed [13]. ASD are
predominately genetically determined disorders with a
heritability of [90% [8]. Among several other chromo-
somal disorders, large deletions and duplications of chro-
mosome 22q11.2 are observed in about 1% of individuals
with ASD [16]. In individuals with chromosome 22q11
deletion syndrome, autistic symptoms are increased, with
about 20–50% meeting the diagnostic criteria of ASD [30].
Therefore, candidate genes in this region might either
influence the phenotypic expression and severity of ASD or
might even be causal in their etiology. The adenosine A2A
receptor gene (ADORA2A) is located on 22q11.23. Studies
in humans have shown an association of single variants
in ADORA2A with panic disorder [7, 9], caffeine or
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D-amphetamine-induced anxiety [1, 6, 11], as well as
individually differing sleep patterns [21]. In addition, ani-
mal studies have implicated the adenosine A2A receptor
(A2AR) in locomotion, anxiety, inhibition of excitatory
neuronal activity and sleep regulation [12, 18]. Besides
high rates of anxiety disorders, motor problems and diffi-
culties regulating sleep are often observed in ASD indi-
viduals [13].
ADORA2A codes for the A2AR, which is expressed
predominantly in enkephalin-expressing GABAergic stri-
atopallidal neurons of the basal ganglia, with highest
expression in the caudate nucleus. Here, A2A adenosiner-
gic, D2 dopaminergic and glutamatergic systems interact
structurally and functionally [5, 22]. As brain imaging
studies strongly implicated the caudate nucleus in the
pathogenesis of ASD [25], the striatal enkephalinergic
system was down-regulated in an animal model of autism
[23], and neuropathological studies have implicated the
glutamatergic system in autism [19]. ADORA2A is a
promising candidate for genetic association studies in
ASD. In this case–control study, we assessed eight SNPs in
ADORA2A for association with the diagnosis of ASD, as
well as with phenotypic variability in autistic symptoms
and history of anxiety, in a sample of 98 individuals with
ASD.
Methods
Sample
A sample of 98 Caucasian individuals with ASD (8
females; 8.2%) were recruited from an ASD specialty
clinic at the Department of Child and Adolescent Psychi-
atry of the Saarland University Hospital, Germany.
Informed consent was obtained from participants and/or
parents. The study design was approved by the local ethical
committee (A¨rztekammer des Saarlandes, Germany).
Inclusion criteria were as follows: diagnosis of autism,
Asperger syndrome or atypical autism according to DSM-
IV; IQ or developmental quotient C35. The Autism
Diagnostic Interview-revised (ADI-R) [15, 20] was con-
ducted with the parent or primary caregiver, and the
behavior of the children and adolescents was directly
observed by the Autism Diagnostic Observation Schedule-
generic (ADOS-G) [4, 14]. Intelligence testing was per-
formed by the German version of the Griffith mental
developmental scales, the Snijders-Oomen non-verbal
intelligence test (2.5–7) [27], the German version of the
Kaufman-assessment battery for children [17] or the
Wechsler scales for children or adults [28, 29]. Most par-
ticipants (98%) were first diagnosed with ASD when the
genetic and phenotypic data were obtained. For 14
individuals (6 autism, 8 Asperger syndrome) detailed ADI-
R data could not be obtained, either because parents were
not available or because the ADI-R was performed outside
the clinical setting.
The standardized medical history included a thorough
pre- and perinatal history, birth parameters, developmental
milestones, presence of any medical or neurological dis-
order including febrile seizures, epilepsy, cerebral palsy,
tuberous sclerosis, neurofibromatosis or any brain anomaly.
Additionally, a thorough review of medical records and a
standardized medical and neurological exam were per-
formed, and the psychotropic/antiepileptic medication sta-
tus was noted. High-resolution karyotyping as well as
molecular genetic assessment of fragile-X-syndrome and
chromosome 15q11–13 duplication was obtained for the
majority of ASD individuals (95%).
Exclusion criteria were as follows: IQ or developmental
quotient \35; birth weight \2,000 g; structural brain
anomaly; tuberous sclerosis, neurofibromatosis, cerebral
palsy, any other neurological disorder with the exception of
a history of febrile or epileptic seizures; microcephaly,
dysmorphic features, cleft palate, cardiac anomaly,
immune deficiency, chronic medical disorder; non-Cauca-
sian parent; maternal antiepileptic or psychotropic medi-
cation during pregnancy. Individuals with a cytogenetic
anomaly, fragile-X-syndrome, chromosome 15q11–13
duplication, Angelman syndrome, Prader–Willi syndrome,
Rett syndrome or any other genetically diagnosed syn-
drome or disorder were excluded from the study. These
strict exclusion criteria were chosen to improve genetic and
phenotypic homogeneity of the ASD sample by exclusion
of individuals with a known genetic risk factor for ASD or
possible phenocopies of the disorder.
The control sample of 234 Caucasian individuals (20
females; 8.6%) was recruited at the Institute of Transfusion
Medicine of the University Hospital, Mu¨nster, Germany. In
these individuals (unrelated healthy anonymous blood
donors), major psychiatric, neurological or internal disor-
ders were excluded by taking a detailed medical history, and
performing a physical examination and various laboratory
tests. The study was approved by the Ethical Committee of
the University of Muenster and written informed consent
was obtained from all participating control subjects.
Genotyping
On the basis of previous association studies [1, 6, 10, 11]
and the Hapmap database (data rel 16, on NCBI B34
assembly, dbSNP b124, http://www.hapmap.org), eight
SNPs (Fig. 1) were chosen to cover the long form of
ADORA2A (25 kb, UCSC Genome Browser, Human Mar.
2006 Assembly) and its ±10 kb flanking regions (tagging
SNPs: rs5751862, rs2298383, rs3761422, rs2236624,
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rs4822492; exonic SNPs: rs5760405 (263C/T), rs5751876
(1976C/T), rs35320474 (2592T/-)). Genotyping was
carried out as described previously [1, 7, 10] except for
SNPs rs2298383 and rs2236624. For these, standard PCR
was carried out in 20 ll volume, containing 60 ng DNA,
10 pM of each primer (MWG Biotech), 200 lM dNTPs
(Fermentas), 0.4 U Taq Polymerase (Eppendorf), 2.5 mM
MgCl2 (Eppendorf), 19 buffer (Eppendorf) and H2O:
initial 5-min denaturation (94C) preceded 35 cycles (30 s
at 94C, 30 s at 60C and 60 s at 72C) and final extension
(10 min at 72C; Biometra). The PCR products were
restricted as recommended by the manufacturer (HpaII for
rs2298383 and MnlI for rs2236624; Fermentas), separated
on 15% polycrylamide gels (acrylamide:bisacrylamide =
37.5:1) at 230 V/cm for 2 h RT and visualized by silver
staining. For genotyping quality control, randomized
probands were re-genotyped (N = 41) or re-sequenced
(N = 3) for all eight SNPs, resulting in concordance rates
of 100% for both techniques. Genotyping yielded a com-
pletion rate of 100% in patients and control individuals
except for one patient (62.5%). All genotypes were deter-
mined to be blind to the disease status.
All SNPs were in Hardy–Weinberg equilibrium (HWE)
in controls. SNPs rs5751862 (P = 0.061), rs2298383
(P = 0.064), rs2236624 (P = 0.026) and rs4822492
(P = 0.082) showed reduced heterozygosity in cases.
Therefore, possible genomic gain or loss of ADORA2A was
investigated by TaqMan-based quantitative real-time PCR
(Applied Biosystems) focusing on SNP rs3761422, which
is located between rs2298383 and rs2236624. PCRs were
run in 10 ll reactions as triplicates following the suppliers’
recommendations. DNA concentrations were normalized to
the three reference genes, 5HT1A (rs6295), RGS4
(rs10917671) and NPY (rs16474). Inter-assay variability
(delta CT) between these genes and ADORA2A was
determined using ten individuals recruited from the control
sample. To normalize data, delta CT was calculated using
as calibrator the mean of the respective delta CTs. Based
on these controls, the mean haploid value was 1.01 with a
standard deviation (SD) of 0.10. A conservative threefold
SD threshold was used to assign a normal copy range
of 0.71–1.31. Five ASD individuals were suspected of
carrying a deletion (haploid value \0.71), and two of
carrying an amplification (haploid value[1.31) within the
ADORA2A locus. None of the control individuals showed a
copy number variation (CNV) of ADORA2A. To control for
false-positive findings due to possible CNVs in the ASD
sample, statistical analyses were performed on the full
sample as well as on the sample without these seven ASD
individuals.
Statistical analysis
Descriptive data were compared by t test, parametric or
nonparametric analysis of variance, v2 or Fisher’s exact test
as appropriate. Hardy–Weinberg equilibrium of SNPs in
cases and controls, as well as pairwise linkage disequilib-
rium of SNPs (D0, R2), was assessed by Haploview version
4.0 (http://www.broad.mit.edu/mpg/haploview). Associa-
tion analyses of case/control status with genotypes were
performed by v2 tests. Haplotype association tests were
done by Haploview version 4.0. Haplotypes from the eight
SNPs were reconstructed on an individual level by PHASE,
version 2.11 [26], based on a probability of reconstructed
pairs of haplotypes for each individual [0.99. Haplotypes
could not be reconstructed for two ASD and one control
subject. Five haplotypes with a frequency of[10% in cases
and controls were assessed as either present or absent
(ACTCCCTG, 44.4%; ATTCCCTG, 40.1%; GCCTCT-C,
28.0%; GCCTTT-C, 37.7%; GCTCCCTG, 21.9%; as each
individual carries two haplotypes, percentages sum up to a
value of\200%). Exploratory association analyses of geno-
and haplotypes with variable phenotypic expression within
the ASD group were performed by multivariate analysis of
Fig. 1 Pairwise linkage
disequilibrium of 8 ADORA2A
SNPs. a D0, b R2
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covariance (MANCOVA) with adjustment for sex, age, IQ
and psychotropic/antiepileptic medication on the three
dependent variables: ADI-R symptom domain scores of
current social interaction, current non-verbal communica-
tion and current repetitive behavior. Current, but not age
4–5 years old, ADI-R symptom domain scores were chosen
as dependent variables, as they are less likely to be inflated
by reporting bias. MANCOVA residuals were normally
distributed. Logistic regression analysis with adjustment for
sex, age, IQ, and psychotropic/antiepileptic medication was
performed to elicit the genetic influence on history of severe
anxiety (ADI-R codings 2, 3). Statistics were calculated by
SAS (SAS/STAT, version 8.2, Cary, BC: SAS Institute Inc.,
1999–2001). Power analysis was performed by Quanto,
version 1.2.3 (http://hydra.usc.edu/GxE).
Results
Descriptive data of the ASD sample are shown in Table 1.
As expected from the diagnostic criteria, the three clinical
groups differed with regard to IQ and autism-specific
symptom severity. The sample was predominately a sample
of high-functioning individuals with IQ C 70 (N = 68;
69.4%). Two SNPs (rs2298383 and rs2236624) were
nominally associated with ASD in the genetic case–control
analysis (Table 2). The association was mainly due to
reduced heterozygosity in ASD subjects. Due to reports of
increased autistic traits in individuals with 22q11.2 deletion
and the relatively frequent occurrence of CNVs throughout
the genome in individuals with ASD [24], analysis was
repeated for the ASD subgroup of 91 individuals without
suspected deletion or amplification within the ADORA2A
locus (see above). SNP rs2236624 remained nominally
associated with ASD (v2 = 8.0, 2 df, P = 0.018) with
higher rates of CC (71.1%) and reduced rates of CT
(21.1%), compared to controls. Global haplotype associa-
tion analysis in the full and the reduced sample was
negative (data not shown).
In the seven individuals with suspected CNV of
ADORA2A, the frequency of rs5751862, rs5760405 and
rs2236624 did not differ compared to controls. For
rs2298383, rs3761422, rs5751876, rs35320474 and
rs4822492 (Fisher’s exact test P(all) = 0.010), no hetero-
zygote genotypes were observed; four individuals carried
the more frequent homozygote genotype and three carried
the less frequent homozygote genotype, respectively.
Haplotype frequency did not differ from controls.
The contribution of ADORA2A to explain phenotypic
variability within ASD individuals without suspected
ADORA2A CNV was assessed by explorative association
analyses of genotypes and haplotypes with ADI-R derived
phenotypic measures and history of severe anxiety. In
Table 3, results of the single SNP genotype analysis are
reported. Increased ADI-R current social interaction, non-
verbal communication and repetitive behavior scores (i. e.,
more autism-specific impairment) were observed in
carriers of rs3761422-CT/TT, rs5751876-CT/TT and
rs35320474-T-/–. These SNPs are tightly linked showing
almost equal genotype frequencies in ASD (Table 2). The
corresponding haplotype GCCTTT-C similarly showed a
trend to be associated with autism-specific symptom
Table 1 Descriptive data
Autism
N = 61
(62.2%)
Asperger
syndrome
N = 25 (25.5%)
Atypical autism
N = 12 (12.2%)
Differences
between groups
F (df)/v2 (df)
P value
Females [N (%)] 7 (11.5) 2 (8.0) 1 (8.3) NS
IQ [mean (SD)] 78.2 (25.7) 101.4 (17.8) 79.7 (18.2) 15.1 (2) 0.0005
Age [mean (SD)] 10.5 (5.7) 12.6 (5.2) 12.0 (8.7) NS
ADI-R algorithm social interaction [mean (SD)]
Current 12.2 (3.6) 10.2 (5.2) 6.2 (4.4) 11.1 (2) \0.0001
Age 4–5 years old 19.9 (5.3) 16.4 (5.4) 14.8 (5.6) 6.0 (2) 0.004
ADI-R algorithm non-verbal communication [mean (SD)]
Current 8.8 (3.8) 4.2 (2.9) 3.6 (3.6) 17.3 (2) \0.0001
Age 4–5 years old 10.8 (2.8) 6.5 (3.2) 5.7 (3.1) 24.0 (2) \0.0001
ADI-R algorithm repetitive behavior [mean (SD)]
Current 5.9 (2.6) 4.7 (2.1) 3.4 (3.1) 5.4 (2) 0.006
Age 4–5 years old 7.0 (2.6) 5.3 (2.1) 4.9 (3.7) 4.8 (2) 0.010
ADI-R history of severe anxiety [N (%)] 12 (19.7) 5 (20.0) 2 (16.7) NS
Psychotropic or antiepileptic medication [N (%)] 15 (24.6) 3 (12.0) 12 (16.7) NS
df degrees of freedom; F, F value; SD standard deviation; NS, P [ 0.10
70 Eur Child Adolesc Psychiatry (2010) 19:67–74
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severity (Table 4). History of severe anxiety was observed
more often in carriers of haplotype ACTCCCTG (Table 4).
Of the individuals with history of severe anxiety, 73.3%
carried this haplotype, whereas of the individuals without
anxiety, only 33.9% carried haplotype ACTCCCTG. The
correct classification was 76.6%. No association of anxiety
with single SNPs was observed.
Of the seven ASD individuals with suspected CNV
within the ADORA2A locus, four carried a diagnosis of
autism and three a diagnosis of Asperger syndrome; all
were male. When these individuals were compared to the
91 ASD individuals without suspected ADORA2A CNV
with regard to phenotypic measures, the following differ-
ences were found: IQ (mean 73.0; SD 17.5) was slightly
lower in the suspected CNV group. Similarly, ADI-R
current social interaction (mean 12.0; SD 2.6), verbal
(mean 15.2; SD 2.5) and non-verbal (mean 8.8; SD 1.5) as
well as repetitive behavior scores (mean 6.6; SD 1.1) were
slightly increased in the CNV group; however, the differ-
ences did not approach significance. The rate of history of
severe anxiety, however, was significantly increased
(P \ 0.0001), possibly due to the relatively frequent
presence of haplotype ACTCCCTG in the CNV group
(57.1%).
Discussion
In this study, eight SNPs in the ADORA2A locus on
chromosome 22q11.23 were assessed in 98 Caucasian
individuals with ASD without dysmorphic features and
sex-matched Caucasian control subjects. The strength of
this study is its rigorous phenotyping of ASD individuals to
increase phenotypic homogeneity and reduce rates of
phenocopies and syndromic ASD in case–control analysis.
To control for possible small CNVs within the ADORA2A
locus not observed by standard cytogenetic testing, Taq-
Man-based quantitative PCR was performed. Seven ASD
individuals (7%) were suspected of potentially carrying a
small CNV. This seems to be relatively high, compared to
the reported rate of 7–44% CNVs in a genome-wide
analysis [16, 24], taking into account the expected differing
CNV rates of locus- versus genome-wide studies. It might
be due to the conservative cutoff of 3 SD used in the study,
Table 2 Genotypes in cases
and controls
df degrees of freedom
* P \ 0.05
SNP Localization ASD
(N = 98)
N (%)
Controls
(N = 234)
N (%)
Differences
between groups
v2 (df)
P value
rs5751862 9.5 kb, 50 flank AA 30 (30.6) AA 57 (24.4) 3.0 (2) 0.227
AG 39 (39.8) AG 117 (50.0)
GG 29 (26.6) GG 60 (25.6)
rs5760405 (263C/T) Exon I CC 58 (59.2) CC 140 (59.8) 0.8 (2) 0.659
CT 31 (31.6) CT 79 (33.8)
TT 9 (9.2) TT 15 (6.4)
rs2298383 Intron I CC 18 (18.6) CC 33 (14.1) 6.2 (2) 0.045*
CT 36 (37.1) CT 122 (52.1)
TT 43 (44.3) TT 79 (33.8)
rs3761422 Intron I CC 45 (45.9) CC 89 (38.0) 3.5 (2) 0.172
CT 38 (38.8) CT 117 (50.0)
TT 15 (15.3) TT 28 (12.0)
rs2236624 Intron IV CC 69 (71.1) CC 136 (58.1) 7.7 (2) 0.021*
CT 21 (21.7) CT 87 (37.1)
TT 7 (7.2) TT 11 (4.7)
rs5751876 (1976C/T) Exon 5 CC 44 (44.9) CC 89 (38.0) 2.9 (2) 0.230
CT 39 (39.8) CT 117 (50.0)
TT 15 (15.3) TT 28 (12.0)
rs35320474 (2592T/-) Exon 5 – 15 (15.5) – 28 (12.0) 3.9 (2) 0.142
T- 37 (28.1) T- 117 (50.0)
TT 45 (46.4) TT 89 (38.0)
rs4822492 5.5 kb 30 flank CC 18 (18.4) CC 33 (14.1) 5.7 (2) 0.057
CG 37 (37.8) CG 122 (52.1)
GG 43 (43.9) GG 79 (33.8)
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which was chosen to exclude individuals with a possible
CNV from the association study to prevent false-positive
findings. In addition, the TaqMan-based technology allows
the detection of smaller CNVs in the size of a few kilobases
compared to the previously applied comparative genomic
hybridization technology. As ADORA2A duplications or
deletions have neither been reported in the database of
genomic variants (http://projects.tcag.ca/variation) nor in
this control sample, but large deletions and duplications of
22q11.2 have been observed in individuals with ASD [16],
these preliminary findings support the notion that
ADORA2A or other closely located genes might be of
relevance to ASD. Our rigorous, conservative approach
resulted in limited power to detect genetic risk factors of
minor effects in case–control analysis. Only a genetic rel-
ative risk between 1.9 (minor allele frequency 0.14–0.17)
and 1.7 (minor allele frequency [0.26) could be detected
with a power of [0.80 in the sample of 91 individuals
without suspected CNVs. The nominal association of
rs2236624-CC as risk genotype with an odds ratio of 1.6
Table 3 Association of genotypes with phenotypic variability in ASD subjects without suspected CNV
rs3761422 rs5751876 rs35320474
ADI-R algorithm current social interaction score
[meana (SE)]
CC 9.7 (1.2) CC 9.7 (1.2) – 12.7 (1.6)
CT 13.5 (1.3) CT 13.5 (1.3) T- 13.3 (1.2)
TT 12.6 (1.7) TT 12.6 (1.7) TT 9.7 (1.1)
ADI-R algorithm current non-verbal communication score
[meana (SE)]
CC 5.9 (1.1) CC 5.9 (1.1) – 8.8 (1.5)
CT 8.2 (1.2) CT 8.2 (1.2) T- 8.0 (1.2)
TT 8.7 (1.5) TT 8.7 (1.5) TT 5.9 (1.1)
ADI-R algorithm current repetitive behavior score
[meana (SE)]
CC 3.9 (0.7) CC 3.9 (0.7) – 5.6 (1.0)
CT 5.3 (0.7) CT 5.3 (0.7) T- 5.2 (0.7)
TT 5.7 (1.0) TT 5.7 (1.0) TT 3.9 (0.7)
MANCOVA
Wilks-Lambda, F (Num df, Den df), P value
0.83, 2.4 (6, 140) 0.83, 2.4 (6, 140) 0.83, 2.2 (6, 138)
0.033 0.034 0.040
Only SNPs associated with phenotypic variability (MANCOVA P value\0.050) are reported. No association was observed of single SNPs with
history of severe anxiety, current hyperactivity or history of epilepsy
df degrees of freedom; F, F value; MANCOVA multivariate analysis of covariance; SE standard error of mean
a Mean value adjusted for age, sex, IQ and medication status
Table 4 Association of haplotypes with phenotypic variability in ASD subjects without suspected CNV
Haplotype
ACTCCCTG
N = 40 (44.0%)
Haplotype
GCCTTT-C
N = 27 (29.7%)
ADI-R algorithm current social interaction score
[meana (SE)]
(1) 12.5 (1.4)
(0) 10.9 (1.1)
ADI-R algorithm current non-verbal communication score
[meana (SE)]
(1) 9.1 (1.2)
(0) 6.4 (1.0)
ADI-R algorithm current repetitive behavior score
[meana (SE)]
(1) 5.4 (0.8)
(0) 4.4 (0.6)
MANCOVA Wilks-Lambda, F value (Num, Den df), P value 0.9, 2.5 (3, 70) 0.065
ADI-R history of severe anxiety OR = 5.5
(95% CI 1.5–20.6)
Statistic: Wald v2 (df) P value 6.5 (1) 0.011
Lowest P values for MANCOVA on ADI-R scores were reported. For history of severe anxiety, only the haplotype associated with phenotypic
variability (P value \0.050) is reported
(1) haplotype present, (0) haplotype not present
CI confidence interval; df degrees of freedom; F, F value; SE standard error of mean; OR Odds ratio, adjusted for age, sex, IQ and medication
status
a Mean value adjusted for age, sex, IQ and medication status
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(95% CI 1.3–2.3) compared to CT, therefore, might have
occurred by chance and needs to be replicated in a larger
sample with sufficient power. rs2236624 is located in
intron IV, but has been reported to show intermediate
regulatory potential (http://genome.ucsc.edu). It is in strong
LD with neighboring SNPs, of which rs2298383 and
rs3761422 might be located in one of the potential pro-
moter regions upstream of several newly identified
ADORA2A exon 1 variants, and therefore might be func-
tionally relevant [31].
Single SNPs and haplotypes, additionally, were nomi-
nally associated with parent-reported phenotypic variability
within ASD subjects. The observed findings have to be
viewed with caution, as parental report of autistic symptoms
might be biased and the findings do not withstand multiple
testing. History of severe anxiety was associated with
haplotype ACTCCCTG, but not with genotypes of single
SNPs. Previous studies on panic disorder and anxiety
reported preferential transmission of the rs5751876 C-allele
and also co-segregation of the T-allele in some families in a
family-based study [9], or reported the T-allele as risk allele
for anxiety induced by D-amphetamine or caffeine [6, 11]
and panic disorder [7]. These findings might be indicative of
a functional variant in strong LD with rs5751876 increasing
the risk for anxiety not only in healthy or panic disorder
subjects, but also in individuals with ASD. The additional
findings of our study have to be interpreted in a hypotheses-
generating way. The nominal association with autism-spe-
cific symptom severity of three tightly linked SNPs and the
corresponding haplotype does not correspond to the nomi-
nally associated intronic rs2236624 and might have occur-
red by chance only. Results again need to be replicated in
larger sample with increased power.
The limitations of the study are first related to the control
group, which was not screened explicitly for ASDs. This
might have resulted in reduced power, as prevalence of
ASD was estimated around 1% [3]. In addition, population
stratification cannot fully be excluded; however, inclusion
of Caucasian individuals only argues against the strong
effects of population stratification. The possible role of
ADORA2A variants in the pathogenesis of ASD is
emphasized by the association of single SNPs with pheno-
typic variability in ASD subjects. The observed associations
did not withstand multiple testing. However, as all SNPs
were in strong LD, and the three SNPs that were associated
with increased autism-specific psychopathology did show
almost similar genotype frequencies, Bonferroni correction
would have underestimated a true association and would
have resulted in the risk of false-negative reporting.
Taken together, we reported a nominal association of
ADORA2A rs2236624 with ASD and replicated ADORA2A
variants as risk factors for anxiety not only in healthy, but
also in ASD individuals. The findings of this study need to
be replicated in a larger sample with sufficient power to also
detect variants with a small genetic relative risk.
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